8-K: Sanuwave Health Reports Q1 2026 Financial Results

Sanuwave Health announced first-quarter 2026 financial results, showing a 3.1% revenue increase to $9.6 million, with guidance for continued growth.

Summary

• Sanuwave Health reported first-quarter 2026 revenues of $9.6 million, a 3.1% increase from $9.3 million in the first quarter of 2025, marking the highest Q1 revenue in company history.
• Gross margin for Q1 2026 was 77.3%, a slight decrease from 79.0% in Q1 2025, attributed to lower pricing on Ultramist systems and applicators sold through resellers.
• The company reported a GAAP operating loss of $1.1 million for Q1 2026, a significant swing from an operating income of $0.6 million in Q1 2025.
• Net loss for Q1 2026 was $1.4 million, an improvement from a net loss of $6.1 million in Q1 2025, largely due to a significant non-cash loss on derivative liabilities in the prior year.
• Adjusted EBITDA for Q1 2026 was $1.1 million, down from $2.3 million in Q1 2025.
• The company provided guidance for Q2 2026 revenue growth of 10-15% compared to Q2 2025 and reiterated full-year 2026 revenue guidance of $51.0-55.0 million (16-25% increase from 2025).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a cautiously optimistic report, with revenue growth and record consumable volumes being positive, but offset by declining margins and operating losses.

Positives

• First quarter 2026 revenues reached $9.6 million, representing a 3.1% increase year-over-year and the highest Q1 revenue in company history.
• Ultramist consumables revenue increased by 15.0% to $6.7 million in Q1 2026 compared to the same period last year.
• Unit volumes on consumables for Q1 2026 set a new all-time record.
• Net loss improved significantly to $1.4 million in Q1 2026 from $6.1 million in Q1 2025.
• The company is hiring salespeople and expanding its reseller network.
• Q2 2026 revenue is projected to increase by 10-15% year-over-year.
• Full-year 2026 revenue guidance remains strong at $51.0-55.0 million, representing a 16-25% increase compared to 2025.

Negatives

• Gross margin as a percentage of revenue decreased to 77.3% in Q1 2026 from 79.0% in Q1 2025, due to lower pricing on systems and applicators sold through resellers.
• The company experienced a GAAP operating loss of $1.1 million in Q1 2026, a reversal from an operating income of $0.6 million in Q1 2025.
• Adjusted EBITDA decreased to $1.1 million in Q1 2026 from $2.3 million in Q1 2025.
• Ultramist system unit sales decreased to 97 in Q1 2026 from 98 in Q1 2025.

Risks

• Risks associated with regulatory oversight.
• The company's ability to manage its capital resources.
• Competition within the wound care market.
• Potential impact of changes in reimbursement levels and tariff rates.

Future Outlook

The company forecasts Q2 2026 revenue of $11.1 to $11.6 million (10-15% increase from Q2 2025) and reiterates full year 2026 revenue guidance of $51.0-55.0 million (16-25% increase as compared to full year 2025 revenue). Management expressed increasing optimism and a robust pipeline exiting the quarter.

Management Comments

• "The recovery appears to have begun in February and to have continued thereafter."
• "Q1 started with a sort of shock pause as many seemed surprised that the changes in reimbursement for skin subs had actually taken effect, and this seems to have contributed to a very slow first month of the year which, in turn, had a large effect on the overall quarter."
• "But, at least from our standpoint, we see the ice starting to break up and the quarter got better each month."
• "Unit volumes on consumables for Q1 2026 set a new all-time record by a significant margin which we take to be a good sign with regard to utilization recovering."
• "All in all, we exited the quarter with increasing optimism and a robust pipeline and we expect to see 2026 continue to get better from here."

Industry Context

StockSavvy.ai notes that Sanuwave Health's Q1 2026 results reflect a challenging but potentially recovering market in advanced wound care, with the company experiencing revenue growth despite margin pressures and a shift in sales channels.

Comparison to Industry Standards

• The reported Q1 2026 revenue growth of 3.1% is within the company's previously guided range of 3-10% for the quarter.
• The decrease in gross margin percentage, while noted, is explained by a strategic shift towards reseller pricing, a common practice in medical device sales to achieve broader market penetration.
• The company's full-year revenue guidance of 16-25% growth positions it for expansion within the wound care sector, which is influenced by factors like an aging population and increasing prevalence of chronic wounds.

Stakeholder Impact

• Shareholders: The report indicates revenue growth and a positive outlook, but also highlights margin pressures and operating losses, which could impact investor sentiment.
• Employees: Continued hiring of salespeople suggests potential job growth and investment in sales infrastructure.
• Customers: Increased consumable sales indicate continued or growing utilization of Sanuwave's products by healthcare providers.

Next Steps

• Conduct a business update conference call on May 13, 2026.
• Continue hiring salespeople and expanding the reseller network.
• Focus on continued revenue growth throughout 2026.

Key Dates

Recommendation

The company shows revenue growth and a positive outlook, but the decrease in gross margin and the swing to an operating loss warrant a cautious approach. Continued monitoring of margin trends and execution of the growth strategy is advised.

Keywords

Sanuwave Health, 8-K, Financial Results, Q1 2026, Revenue, Wound Care, Ultramist, Adjusted EBITDA